SG11202109512SA - Leucine, acetyl leucine, and related analogs for treating disease - Google Patents

Leucine, acetyl leucine, and related analogs for treating disease

Info

Publication number
SG11202109512SA
SG11202109512SA SG11202109512SA SG11202109512SA SG11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA SG 11202109512S A SG11202109512S A SG 11202109512SA
Authority
SG
Singapore
Prior art keywords
leucine
acetyl
treating disease
related analogs
analogs
Prior art date
Application number
SG11202109512SA
Other languages
English (en)
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG11202109512SA publication Critical patent/SG11202109512SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202109512SA 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease SG11202109512SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
SG11202109512SA true SG11202109512SA (en) 2021-09-29

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109512SA SG11202109512SA (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Country Status (25)

Country Link
US (1) US20220142959A1 (https=)
EP (2) EP4464378A3 (https=)
JP (2) JP7555346B2 (https=)
KR (2) KR102941068B1 (https=)
CN (2) CN119097618A (https=)
AU (2) AU2020231189B2 (https=)
BR (1) BR112021017203A2 (https=)
CA (1) CA3131948A1 (https=)
DK (1) DK3934637T3 (https=)
ES (1) ES2990183T3 (https=)
FI (1) FI3934637T3 (https=)
HR (1) HRP20241150T1 (https=)
HU (1) HUE068527T2 (https=)
IL (2) IL321899A (https=)
LT (1) LT3934637T (https=)
MA (1) MA55199B1 (https=)
MD (1) MD3934637T2 (https=)
MX (2) MX2021010568A (https=)
PL (1) PL3934637T3 (https=)
PT (1) PT3934637T (https=)
RS (1) RS65849B1 (https=)
SG (1) SG11202109512SA (https=)
SI (1) SI3934637T1 (https=)
SM (1) SMT202400334T1 (https=)
WO (1) WO2020178721A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
US20250025442A1 (en) * 2020-12-10 2025-01-23 Texas Tech University System BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
ES2994242T3 (en) * 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
JP7370960B2 (ja) * 2017-08-14 2023-10-30 アクセラ・ヘルス・インコーポレイテッド 神経細胞損傷の治療のためのアミノ酸組成物

Also Published As

Publication number Publication date
CN114040757A (zh) 2022-02-11
BR112021017203A2 (pt) 2021-12-14
US20220142959A1 (en) 2022-05-12
IL321899A (en) 2025-09-01
EP3934637A1 (en) 2022-01-12
HUE068527T2 (hu) 2025-01-28
SI3934637T1 (sl) 2024-10-30
JP7555346B2 (ja) 2024-09-24
IL285870B2 (en) 2025-12-01
AU2020231189A1 (en) 2021-09-30
KR20250171484A (ko) 2025-12-08
HRP20241150T1 (hr) 2024-11-22
AU2020231189B2 (en) 2025-07-24
MD3934637T2 (ro) 2024-12-31
EP4464378A3 (en) 2025-04-09
DK3934637T3 (da) 2024-09-02
CN119097618A (zh) 2024-12-10
EP4464378A2 (en) 2024-11-20
RS65849B1 (sr) 2024-09-30
MA55199A (fr) 2022-01-12
KR20210135272A (ko) 2021-11-12
IL285870B1 (en) 2025-08-01
JP2022522819A (ja) 2022-04-20
MX2021010568A (es) 2021-11-12
WO2020178721A1 (en) 2020-09-10
IL285870A (en) 2021-10-31
FI3934637T3 (fi) 2024-09-02
JP2024170602A (ja) 2024-12-10
ES2990183T3 (es) 2024-11-29
EP3934637B1 (en) 2024-07-31
SMT202400334T1 (it) 2024-09-16
CA3131948A1 (en) 2020-09-10
MX2024015063A (es) 2025-01-09
PL3934637T3 (pl) 2024-10-14
MA55199B1 (fr) 2024-08-30
CN114040757B (zh) 2024-09-20
KR102941068B1 (ko) 2026-03-18
PT3934637T (pt) 2024-08-30
AU2025204995A1 (en) 2025-07-17
LT3934637T (lt) 2024-08-26

Similar Documents

Publication Publication Date Title
SG11202109512SA (en) Leucine, acetyl leucine, and related analogs for treating disease
IL285782A (en) Compounds, compositions, and methods for treating disease
IL288958A (en) Exosomes for the treatment of diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL286000A (en) Asketamine for the treatment of depression
GB201916237D0 (en) Novel treatment
IL288937A (en) Improved treatment using eyp001
SI3834594T1 (sl) Kolo s strgalom za sejalnik
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
EP3927375A4 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB201913988D0 (en) Novel treatment
IL291640A (en) Compounds of 1,8-naphthyridin-2-one for the treatment of autoimmune disease
GB201908453D0 (en) Compounds for treating respiratory disease
GB201914296D0 (en) Treatment
IL289440A (en) A process for deprotection of oligonucleotides
HUE065591T2 (hu) Gyógyszer fertõzõ betegségek kezelésére
GB201911728D0 (en) Bacterial composistions for the treatment of disease
GB201902579D0 (en) Treatment
GB201906969D0 (en) Tissue splayer
IL287840A (en) treatment system
GB201917691D0 (en) Compounds for treating respiratory disease
GB201908451D0 (en) Compounds for treating respiratory disease
HK40063671A (en) Exosomes for disease treatment
IL284747A (en) Minocycline for the treatment of Pitt-Hopkins syndrome
GB202009040D0 (en) Curved chaffer